Anti-edematous effects of tolvaptan in experimental rodent models

Cardiovascular Drugs and Therapy

Volumn 25, Issue SUPPL. 1, 2011, Pages

  Miyazaki, Toshiki ^a   Sakamoto, Yuki ^a   Yamashita, Tatsuya ^a   Ohmoto, Koji ^a   Fujiki, Hiroyuki ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Carrageenan; Edema; Furosemide; Paw volume; Tolvaptan; Vascular permeability

Indexed keywords

FUROSEMIDE; SODIUM; TOLVAPTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIURETIC ACTIVITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; EXPERIMENTAL MODEL; FLUID RETENTION; HYPONATREMIA; MALE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT; SERUM OSMOLALITY; SINGLE DRUG DOSE; SKIN PERMEABILITY; SODIUM BLOOD LEVEL; URINALYSIS; URINE VOLUME;

ANIMALS; BENZAZEPINES; CARRAGEENAN; DISEASE MODELS, ANIMAL; DIURETICS; EDEMA; FOOT DISEASES; HISTAMINE; MALE; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASOPRESSIN; SKIN DISEASES, VASCULAR; SODIUM;

EID: 83655212319     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6355-z     Document Type: Article

References (30)

1. JP Morrison 1997 Edema and principles of diuretic use Med Clin N Am. 81 689 704 9167652 10.1016/S0025-7125(05)70540-X 1:STN:280:DyaK2szhtVCrtw%3D%3D (Pubitemid 27220646)
2. LC Costello-Boerrigter WB Smith G Boerrigter, et al. 2006 Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure Am J Physiol Renal Physiol. 290 F273 8 16189291 10.1152/ajprenal.00195.2005 1:CAS:528:DC%2BD28XhsFKit7Y%3D (Pubitemid 43724981)
3. Palmer BF. Potassium disturbances associated with the use of diuretics. In: Seldin D, Giebisch G, editors. Diuretic agents-clinical physiology and pharmacology. San Diego: Academic; 1997. p. 571-83.
4. Rivera-Santos A, Star R. Sodium: Volume depletion and hyponatremia. In: Seldin D, Giebisch G, editors. Diuretic agents-clinical physiology and pharmacology. San Diego: Academic Pressl; 1997. p. 559-69.
5. A Morel A O'Carrol MJ Brownstein SJ Lolait 1992 Molecular cloning and expression of a rat V1a arginine vasopressin receptor Nature 356 523 6 1560825 10.1038/356523a0 1:CAS:528:DyaK3sXhvVelsbY%3D
6. M Thibonnier C Auzan Z Madhun P Wilkins L Berti-Mattera E Clauser 1994 Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor J Biol Chem 269 3304 10 8106369 1:CAS:528:DyaK2cXis1Wltbg%3D
7. Y De Keyzer C Auzan F Lenne, et al. 1994 Cloning and characterization of human V3 pituitary vasopressin receptor FEBS Lett 356 215 20 7805841 10.1016/0014-5793(94)01268-7 (Pubitemid 24376975)
8. T Sugimoto M Saito S Mochizuki Y Watanabe S Hashimoto H Kawashima 1994 Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor J Biol Chem 269 27088 92 7929452 1:CAS:528: DyaK2cXmvFCisL8%3D
9. M Birnbaumer A Seibold S Gilbert, et al. 1992 Molecular cloning of the receptor for human antidiuretic hormone Nature 357 333 5 1534149 10.1038/357333a0 1:CAS:528:DyaK3sXhvVelt78%3D
10. 2 receptor and possible link to nephrogenic diabetes insipidus Nature 357 336 9 1534150 10.1038/357336a0 1:CAS:528:DyaK3sXhvVelt7w%3D
11. 2 receptor antagonists J Mol Endocrinol 29 1 9 12200224 10.1677/jme.0.0290001 1:CAS:528:DC%2BD38XmvFOhu7w%3D (Pubitemid 34965741)
12. 2 receptor antagonist Bioorg Med Chem 7 1743 54 10482466 10.1016/S0968-0896(99)00101-7 1:CAS:528:DyaK1MXlslWgtLw%3D (Pubitemid 29347138)
13. 2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats J Pharmacol Exp Ther 287 860 7 9864265 1:CAS:528:DyaK1MXjvVShsw%3D%3D (Pubitemid 29131593)
14. 2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats J Pharmacol Exp Ther 292 288 94 10604960 1:CAS:528:DC%2BD3cXhslGktg%3D%3D (Pubitemid 30026383)
15. S Inoue H Kido K Hayashi Y Kubo T Uchida M Watanabe 1996 Effects of a novel loop diuretic, torasemide, on several kinds of edematous models of rats KISO TO RINSHO. 30 489 96
16. PT Veeraveedu K Watanabe M Ma, et al. 2008 Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure Biochem Pharmacol 75 1322 30 18179782 10.1016/j.bcp.2007.11.011 1:CAS:528:DC%2BD1cXislamtLk%3D
17. Y Tsuboi S Ishikawa G Fujisawa K Okada T Saito 1994 Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats Kidney Int 46 237 44 7933842 10.1038/ki.1994.265 1:CAS:528:DyaK2cXlvFGrtLc%3D (Pubitemid 24210457)
18. 2-AVP receptor antagonist, conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites J Hepatol 38 755 61 12763368 10.1016/S0168-8278(03)00116-8 (Pubitemid 36613341)
19. 2-vasopressin receptor antagonist, SR121463, in cirrhotic rats J Pharmacol Exp Ther 295 83 90 10991964
20. 2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention Br J Pharmacol 146 654 61 16113688 10.1038/sj.bjp.0706375 1:CAS:528:DC%2BD2MXhtFKht7jK (Pubitemid 41573616)
21. T Okada T Sakaguchi I Hatamura, et al. 2009 Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats Clin Exp Nephrol 13 438 46 19452240 10.1007/s10157-009-0196-0 1:CAS:528:DC%2BD1MXhsVertrjF
22. D Chabardes M Gagman-Brunette M Imbert-Teboul, et al. 1980 Adenylate cyclase responsiveness to hormones in various portions of the human nephron J Clin Invest 65 439 48 7356689 10.1172/JCI109687 1:CAS:528:DyaL3cXht1ahsrY%3D (Pubitemid 10159874)
23. D Chabardes M Imbert-Teboul M Gagnan-Brunette F Morel 1977 Difference hormone target sites along the mouse and rabbit nephrons Curr Probl Clin Biochem 8 447 54 616378 1:STN:280:DyaE1M%2Fgt1Oqsg%3D%3D
24. DA Hall DM Varney 1980 Effect of vasopressin electrical potential difference and chloride transport in mouse medullary thick ascending limb of Henle's loop J Clin Invest 66 792 802 7419720 10.1172/JCI109917 1:CAS:528:DyaL3cXlvFyit7k%3D (Pubitemid 10060948)
25. F Morel 1981 Sites of hormone action in the mammalian nephron Am J Physiol 240 F159 64 6259951 1:CAS:528:DyaL3MXps1Crsg%3D%3D
26. BT Ruggles N Murayama JL Werness SM Gapstur MD Bentley TP Dousa 1985 The vasopressin-sensitive adenylate cyclase in collecting tubules and in the thick ascending limbs of Henle's loop of human and canine kidney J Clin Endocrinol Metab 60 914 21 2984237 10.1210/jcem-60-5-914 1:CAS:528:DyaL2MXhvFygtbg%3D (Pubitemid 15085122)
27. M Gheorghiade WA Gattis CM O'Connor, et al. 2004 Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial JAMA 291 1963 71 15113814 10.1001/jama.291.16.1963 1:CAS:528:DC%2BD2cXjs1ajsb8%3D (Pubitemid 38544277)
28. MA Konstam M Gheorghiade JC Burnett Jr, et al. 2007 Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial JAMA. 297 1319 31 17384437 10.1001/jama.297.12.1319 1:CAS:528:DC%2BD2sXjs1ejtrg%3D (Pubitemid 46513233)
29. M Gheorghiade MA Konstam JC Burnett, et al. 2007 Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials JAMA. 297 1332 43 17384438 10.1001/jama.297.12.1332 1:CAS:528:DC%2BD2sXjs1ejt7k%3D (Pubitemid 46513234)
30. LKM De Bruyne 2003 Mechanisms and management of diuretic resistance in congestive heart failure Postgrad Med J. 79 268 71 12782772 10.1136/pmj.79.931. 268 (Pubitemid 36724235)